<DOC>
	<DOCNO>NCT01881048</DOCNO>
	<brief_summary>The purpose study evaluate effect two anti-inflammatory drug , fish oil capsule COX-2 inhibitor celecoxib , pregnancy associate breast cancer ( PABC ) . Short-term intervention anti-inflammatory medication demonstrate reduction inflammation immune suppressive phenotype PABC , decrease metastatic potential PABC . This unique window breast cancer management serve valuable opportunity obtain preliminary data biomarkers alteration occur system troubled drug intervention instrumental designing future therapeutic preventative strategy large clinical study .</brief_summary>
	<brief_title>Window Opportunity Study Targeting Inflammatory Milieu</brief_title>
	<detailed_description>This randomize pilot clinical trial study omega-3 fatty acid celecoxib treat patient breast cancer plan undergo surgery . Omega-3 fatty acid may stimulate immune system different way stop tumor cell grow . Celecoxib may stop growth tumor cell block enzymes need cell growth . It yet know whether omega-3 fatty acid celecoxib effective treating breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Histological cytological confirmation breast cancer ; patient fine needle aspiration ( FNA ) , core biopsy must intend For patient diagnosed needle core excisional biopsy , formalinfixed paraffin embed tumor block unstained slide must available patient must willing undergo repeat core biopsy research purpose part study procedure ( biopsy fresh/ fresh frozen tissue otherwise optional ) Any clinical stage allow provide definitive local resection intend neoadjuvant treatment intend Patient must plan proceed definitive surgery breast cancer least 1 week diagnosis Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Total bilirubin = &lt; 2 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) = &lt; 2 x ULN Alanine aminotransferase ( ALT ) = &lt; 2 x ULN Alkaline phosphatase = &lt; 2 x ULN Normal serum creatinine Platelet count great equal institutional low limit normal ( LLN ) Patient great grade 1 anemia determine hematocrit ( Hct ) Written informed consent obtain prior initiation study procedure Willingness abstain either fish oil celebrex study period randomize control arm Women lactate time diagnosis eligible provide complete wean prior start study drug Known autoimmune condition , chronic steroid use , underlie immune disease ( breast cancer ) , use immunomodulatory prescription drug medical condition Known allergy intolerance fish oil , fish , nonsteroidal antiinflammatory drug ( NSAIDS ) , acetylsalicylic acid ( ASA ) cyclooxygenase2 ( COX 2 ) inhibitor Known bleed diathesis history peptic ulcer disease ; gastroesophageal reflux allow control Currently take great one 1000mg fish oil capsule daily celecoxib baseline , unless willing stop consumption 1 week prior start study History stroke , transient ischemic attack ( TIA ) coronary artery disease The presence comorbid condition know impact immune function , ( : type I diabetes , uncontrolled adult onset diabetes , severe chronic obstructive pulmonary disease ( COPD ) , uncontrolled infection know human immunodeficiency virus [ HIV ] infection ) Underlying psychiatric condition would , opinion investigator , preclude compliance study requirement Women pregnant time breast cancer diagnosis intend continue pregnancy ; pregnancy terminate per patient 's cancer decision making , would eligible participation afterwards History malignancy besides current diagnosis breast cancer , unless definitively treat 5 year ago Any history Hodgkin 's disease require mantle field irradiation Any previous diagnosis breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Omega-3 Fatty Acid</keyword>
	<keyword>Celecoxib</keyword>
	<keyword>Celebrex</keyword>
	<keyword>Surgery</keyword>
</DOC>